The following testimonials have been sourced from a number of different blogs and informational reference points across the net, and are all from individuals not seeking financial remuneration from testimonials given. Rather, these are pieces of correspondence from other seekers of the truth, regaling us with their own personal experience with MMS.
Below is a brief rendition from a practitioner who also has been tested positive for HIV.
While I’m at it, I thought I’d share my experience thus far:
An holistic healer friend of mine sent me a bottle of MMS and powdered citric acid a year ago when I found out I was HIV+. I shelved the remedy, and elected to go with traditional medication to keep it in check. Now a year has passed, my health is good, but I found out that MMS can be used for general detox purposes, something we can all use. I’ve also had a nasty case of athlete’s foot for probably 8 months that will NOT go away, no matter what I use to treat it — antifungal sprays, tea tree oil, colloidal silver, and hydrogen peroxide have all been useless.
So I’m on day #5 now, rocketing from 2 drops on Wednesday to 13 drops today. Already I’ve noticed BIG changes in regard to the athlete’s foot, but also some distinct improvements in my mood and brain function. I played a small acoustic show yesterday at a coffeehouse (first one in several years), and had practically no stage fright, which is extremely odd for me. I’ve been getting out of bed around 8:00 feeling refreshed and somewhat chatty (also unusual), and getting tired around 11:00 at night. Is the chlorine dioxide possibly regulating my sleep cycles? I’ve had some D, and a bit of nausea, but it feels good knowing that it’s part of the healing process.
This forum has been extremely helpful as I start this process, and I look forward to more improvements in my health and well-being.
Below is a recent finding of a document about MMS and aids / HIV. The following piece goes into the therapeutic quality of chlorine dioxide, along with the subsequent patents that have been submitted.
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention is concerned with the novel use of a
chemically-stabilized chlorite matrix for the parenteral treatment of HIV infections.
2. Description of Related Art
HIV infections, amongst which the various subsidiary forms of the HIV virus are to be understood, are ever increasing. Despite intensive endeavors to control HIV infections, it has hitherto not been possible to find an absolutely effective counteragent. Previously known agents, for example
AZT or DDI, act especially on the cells infected with the virus, which are thereby killed off so that the infection does not proceed further. But these known agents have no effect on the viruses liberated into the blood circulation by the breakup of such cells, which bring about spreading and
infection of other cells.
Sarin et al., New England Journal of Medicine, 313, 1416/1985, discloses a treatment of cell cultures of HTLV III–(HIV) viruses in vitro with a 200 fold diluted solution of 0.23% sodium chlorite and 1.26% lactic acid. The
treatment of Sarin et al. led to an inactivation of the viruses.
U.S. Pat. No. 5,019,402 discloses a solution containing chlorine dioxide or a chlorine dioxide-liberating mixture of a chlorite, a weakly acidic buffer and a heat-activated saccharide which can be used for the sterilization of stored blood components with the exception of those which
contain red blood corpuscles, i.e., of leukocytes, blood platelets, coagulation factors and globulins. In whole blood, a corresponding disinfecting action does not occur, presumably because the red blood corpuscles are attacked more quickly by the chlorine dioxide than the investigated micro-organisms. Therefore, this agent also is not suitable
for a parenteral administration.
DE-OS 32 13 389, U.S. Pat. No. 4,507,285 and U.S. Pat. No. 4,296,103,
describe chemically-stabilized chlorite matrices which are suitable for an external or oral therapeutic use. Besides various bacterial infections, the external treatment of virus infections, such as herpes simplex and herpes zoster, is deemed possible in this manner but an intravenous
administration for the treatment of HIV infections is not possible.
EP 0 200 155 further describes solutions of a chemically-stabilized chlorite matrix for intravenous and perioperative administration. The agent has proved to be effective in the treatment of Candida albicans
infections. From EP 0 200 157, it is known to use such stabilized chlorite matrices for intravenous and/or local administration in cases of infectious conditions brought about by parasites, fungi, bacteria, viruses and/or mycoplasts. The action is explained by a phagocyte stimulation which is achieved by a single effective administration of the chlorite complex shortly after the infection. Combating virus infections is not described in this publication and, because of the principle of action,
does not appear to be possible.
SUMMARY OF THE INVENTION
It is an object of the present invention to provide an agent which inactivates HIV viruses in the blood without having a damaging influence on the blood and on the body of the patient.
In accordance with the present invention, there is provided a method of using a chemically-stabilized chlorite matrix for the parenteral treatment of HIV infections consisting of an isotonic solution containing 5 to 100 mMol, and preferably 50 to 80 mMol of ClO2- per liter of
The solution can be used as an injection solution or, after dilution, as an infusion solution.
In accordance with the present invention, there is also provided a method for parenteral treatment of HIV infections comprising administering an inhibition effective amount of a chlorite matrix solution comprising an
isotonic solution comprising 5 to 100 mMol of ClO2- per liter of solution. The method of the present invention causes an inhibition of the infection of undamaged cells as well as a stimulation of T-cells and Natural Killer (NK) cells.
Further objects, features and advantages of the present invention will become apparent from the detailed description of preferred embodiments that follow.
BRIEF DESCRIPTION OF THE DRAWINGS
FIGS. 1 and 1a illustrate the relationship between the concentration of chlorite matrix solution and the infectivity of cell-bound HIV-I or HIV-II.
FIGS. 2 and 2a illustrate the relationship between the concentrations of chlorite matrix solution and the infectivity of non cell-bound HIV-I or HIV-II.
FIG. 3 illustrates the results of Example 3 wherein 4 HIV-I infected patients were treated with chlorite matrix solutions over an extended period of time.
FIG. 4 illustrates the results of Example 4 showing the relationship between the number of T-cells and the period of treatment with the chlorite matrix solutions of the invention.
FIG. 5 illustrates the results of Example 4 showing the relationship between the number of NK cells and the period of treatment with a chlorite matrix solution of the present invention.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
Solutions of sodium and potassium chlorite are known to be disproportionate in acidic solution with the formation of chlorine dioxide and chloride. The chlorites and also chlorine dioxide formed are known to be effective
microbicides for the sterilization of surfaces and solutions. However, the use of chlorite solutions for parenteral administration typically was not thought to be possible because of their extraordinary toxicity.
It is therefore quite unexpected that, with an intravenous administration of an appropriate chlorite matrix in the appropriate concentration, HIV viruses can be directly combated in the blood, demonstrated by the rapid
and strong decrease of the viruses detectable in the blood. The chlorite matrix solutions of the present invention also do not exhibit adverse effects such as severe cytotoxic damage and the like, typically associated with highly toxic chemicals which are administered intravenously. The
chlorite matrix solutions of the present invention further are capable of inactivating the HIV virus to thereby inhibit infection of undamaged cells. The concentration of the HIV virus in serum is typically determined in the known manner by coupling with antibodies against the virus-specific p24 antigen. (S. Mihm et al., (1991) Aids 5, 497-503) The virus-inhibiting action of the chlorite matrix appears to be concentration-dependent. A significant inhibition of a new infection is found in vitro even at concentrations of 5 μmol/l, whereas a concentration of 150 μmol/l brings about a practically complete inhibition. However, concentrations of more than 100 μmol/l can, over a prolonged period of time, lead to cytotoxic damage. Thus, concentrations of from 10 to 100, preferably of from about 40 to 80 and especially of 50 μmol/l are preferred.
The chlorite matrix solutions of the present invention are dosed in vivo corresponding to the body weight, whereby, because of the continuous breakdown of the active material in the blood, the agent must be administered again at regular intervals. Those skilled in the art are
capable of varying the concentrations of virus-inhibiting solutions depending on available in vitro data and body weight. Thus, throughout the specification and claims, the phrase “an inhibition effective amount” will be known by those skilled in the art to mean an amount of solution which, when administered in vivo to subjects of varying weight, will bring about an inhibition of the virus. Typically, an inhibition effective amount of the chlorite matrix solution will vary between about 0.1 ml/kg to about 1.5 ml/kg, preferably, about 0.5 ml/kg of body weight and at a
concentration of about 40 to about 80 mMol ClO2- per liter,
preferably about 60 mMol ClO2- per liter, respectively.
The following examples serve to illustrate particularly preferred embodiments of the present invention. Those skilled in the art recognize that various modifications may be made to the foregoing description and the following examples without departing from the spirit and scope of the